Previous close | 6.23 |
Open | 6.20 |
Bid | 0.00 x 3200 |
Ask | 0.00 x 1800 |
Day's range | 6.15 - 6.49 |
52-week range | 2.87 - 8.58 |
Volume | |
Avg. volume | 3,761,103 |
Market cap | 646.356M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -10.43 |
Earnings date | 02 Mar 2023 - 06 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.33 |
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions